Mariia Iurova

Mariia Iurova


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ATAlisa Tokareva
Alisa Tokareva
MIMariia Iurova
Mariia Iurova
NSNatalia Starodubtseva
Natalia Starodubtseva
VCVitaliy V. Chagovets
Vitaliy V. Chagovets
ANAnastasia Novoselova
Anastasia Novoselova
GSGennady T. Sukhikh
Gennady T. Sukhikh
Ovarian cancer (OC), the third most common gynecologic malignancy, exhibits distinct metabolic alterations that could enable early detection via liquid biopsy. We developed an advanced machine learning pipeline integrating lipidomics (HPLC-MS, positive/negative ion modes) and NMR-based metabolomics to analyze plasma samples from 229 subjects, including 103 serous OC patients, 107 benign cases, and 19 healthy controls. By systematically evaluating feature selection methods and machine learning architectures, we identified optimal biomarker combinations for OC detection. Convolutional Neural Network (CNN) model based on Mann–Whitney-selected features demonstrated strong discriminatory power (81% accuracy) in distinguishing malignant from benign cases, while Extreme Gradient Boosting (XGBoost) combined with Support Vector Machine-Recursive Feature Elimination (SVM-RFE) achieved exceptional performance (96% accuracy) in differentiating benign from control samples. For multiclass classification, XGBoost with Kruskal–Wallis-selected features achieved 77% accuracy, while one-versus-one CNN models utilizing Mann–Whitney-selected features attained 78% accuracy, demonstrating optimal performance among tested approaches. The complementary strengths of deep learning and ensemble methods underscore their potential for tailored diagnostic applications. While clinical implementation requires further standardization, these findings provide both a methodological framework for metabolic biomarker discovery and biological insights into OC pathophysiology, paving the way for integrated multi-omics approaches in gynecologic oncology.

30 March 2020 in Akusherstvo i ginekologiia
Verified
Journal Article
Closed access
PPPyregov A.V. Pyregov
Pyregov A.V. Pyregov
SSShmakov R.G. Shmakov
Shmakov R.G. Shmakov
FFFеdorova Т.а. Fеdorova
Fеdorova Т.а. Fеdorova
MIMariia Iurova
Mariia Iurova
RRRogachevsky О.V. Rogachevsky
Rogachevsky О.V. Rogachevsky
SSStrelnikova E.V. Strelnikova
Strelnikova E.V. Strelnikova

21 January 2019 in Journal of X-Ray Science and Technology
Verified
Journal Article
Closed access
PDF file
PGPetr V. Glybochko
Petr V. Glybochko
YAYuriy. G. Alyaev
Yuriy. G. Alyaev
SKSergey B. Khokhlachev
Sergey B. Khokhlachev
DFDmitriy N. Fiev
Dmitriy N. Fiev
ESEvgeniy V. Shpot
Evgeniy V. Shpot
MYMaria Yurova
Maria Yurova
Contrast-enhanced multi-slice computed tomography (MSCT) is commonly used in the diagnosis of complex malignant tumours. This technology provides comprehensive and accurate information about tumour size and shape in relation to solid tumours and the affected adjacent organs and tissues. This case report demonstrates the benefit of using MSCT 3D imaging for preoperative planning in a patient with late-stage (T4) sarcomatoid renal cell carcinoma, a rare renal malignant tumour. The surgical margin on the liver was negative, and no metastases to veins, lungs or other organs were detected by abdominal and chest contrast-enhanced CT. Although sarcomatoid histology is considered to be a poor prognostic factor, the patient is alive and well 17 months after surgery. The MSCT imaging modality enables 3D rendering of an area of interest, which assists surgical decision-making in cases of advanced renal tumours. In this case, as a result of MSCT 3D reconstruction, the patient received justified surgical treatment without compromising oncological principles.

10 August 2023 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
MIMariia Iurova
Mariia Iurova
EMElena A. Mezhevitinova
Elena A. Mezhevitinova
OYOksana V. Yakushevskaya
Oksana V. Yakushevskaya
VRValery Vitalievich Rodionov
Valery Vitalievich Rodionov
VPVera N. Prilepskaya
Vera N. Prilepskaya
ЮВЮрова Мария Владимировна
Юрова Мария Владимировна
Hormonal-induced changes in the breast occur due to both endogenous and exogenous sex hormones. For two decades, the safety of hormonal contraceptives (HC) in terms of their effect on breast tissue has been discussed in the literature. The pleiotropic effect of the components in the combined HC, on the one hand, prevents unwanted pregnancy; on the other hand, they help to maintain good health of women of childbearing age due to a wide range of non-contraceptive effects (eliminating hyperandrogenism manifestations, reducing the pain severity during menstruation and the menstrual blood loss, the risk of recurrence of functional ovarian cysts, oncoprotective effect due to reducing the risk of ovarian, endometrial, colorectal, pancreatic, and lung cancer). However, according to epidemiological studies, in addition to the beneficial effects, there are risks that require further study, including the controversial impact of HC on the oncogenesis and progression of breast cancer. In addition, some young women with breast cancer experience induced menopause after antitumor treatment. However, amenorrhea is not a marker for complete disabling of ovarian function, and pregnancy is associated with a risk of disease recurrence or progression. Therefore, in each case, it is necessary to determine the need for an effective and safe method of contraception.

10 June 2024 in GYNECOLOGY
Verified
Journal Article
Open access
PDF file
VPVera N. Prilepskaya
Vera N. Prilepskaya
MIMariia Iurova
Mariia Iurova
ЮВЮрова Мария Владимировна
Юрова Мария Владимировна
The concept of the demographic policy of the Russian Federation is to increase the birth rate, preserve citizens' health, and increase life expectancy. One of the priority areas is the reproductive health of women. The pleiotropic effect of the components of combined hormonal drugs is successfully used in clinical practice by obstetricians-gynecologists not only for contraception but also for conditions requiring prophylaxis and drug therapy. Estrogens have a protective effect on the reproductive and extragenital organs; however, evidence of the effect of estrogen-containing drugs on breast tissue and hemostasis remains debatable. We analyzed the data published in the international databases PubMed, Google Scholar, and MEDLINE (search depth – 5 years). Estetrol (E4) is a native fetal estrogen produced by the fetal liver during pregnancy. The key difference from other estrogens is its highly selective and differentiated effect on various tissues and its unique antiproliferative properties. The review presents the results of studies on estrogenic and antiestrogenic effects of E4 and the combination of E4 with progestogen (Esteretta drug product approved in Russia), with particular attention paid to the oncoprotective effect of E4. Research data suggest that E4 may have different effects on breast epithelial cells and breast cancer cells compared to other estrogens. Clinical data indicate that E4 has a more selective pharmacological profile compared to other estrogens, which is reflected in a low estrogenic effect on the liver, including the production of sex hormone binding globulin, hemostasis parameters, and lipid profile.

28 March 2022 in Akusherstvo i ginekologiia
Verified
Journal Article
Closed access
MIMariia Iurova
Mariia Iurova
CEChupalav Eldarov
Chupalav Eldarov
MBMikhail Bobrov
Mikhail Bobrov
KKKhabas G.N. Khabas
Khabas G.N. Khabas
PPPavlovich S.V. Pavlovich
Pavlovich S.V. Pavlovich